<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451320</url>
  </required_header>
  <id_info>
    <org_study_id>11</org_study_id>
    <nct_id>NCT01451320</nct_id>
  </id_info>
  <brief_title>Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis</brief_title>
  <acronym>TROIA</acronym>
  <official_title>Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite high mortality and morbidity, the best treatment strategies for prosthetic valve&#xD;
      thrombosis (PVT) have been controversial. In this study the investigators wanted to identify&#xD;
      the most effective and safe regimen among different thrombolytic strategies.Transesophageal&#xD;
      echocardiography (TEE) guided thrombolytic treatment was administered to 182 consecutive&#xD;
      patients with PVT in 220 different episodes (156 women, mean age 43.2±13.06 years) between&#xD;
      1993 and 2009. These regimens included rapid streptokinase (Group I, 16 episodes), slow&#xD;
      streptokinase (Group II, 41 episodes), high dose (100 mg) tissue plasminogen activator (t-PA)&#xD;
      (Group III, 12 episodes), half-dose (50 mg) slow infusion (6-hours) of t-PA without bolus&#xD;
      (Group IV, 27 episodes), and low dose (25 mg) and slow infusion (6-hours) of t-PA without&#xD;
      bolus (Group V, 124 episodes). The study endpoints were thrombolytic success and in-hospital&#xD;
      mortality and non-fatal complication rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hundred and eighty two consecutive in-hospital patients with 220 episodes of PVT between&#xD;
      1993 and 2009 were included in the study. The patients were enrolled after informed consent&#xD;
      if there was no contraindication, to thrombolysis. The study was approved by the local Ethics&#xD;
      Board. The patient demographics, past medical history, date of the operation, type and make&#xD;
      of the prosthetic valve, rhythm disorders, aspirin use, NYHA functional capacity, leading&#xD;
      symptoms and international normalization ratio (INR) values at the time of admission were&#xD;
      prospectively entered into a database.The diagnosis of PVT was verified each time by&#xD;
      transesophageal echocardiography (TEE) when a patient was admitted with thromboembolism or&#xD;
      persistently low INR for the preceding consecutive 3 months and when a transthoracic&#xD;
      echocardiography (TTE) documented prosthetic valve dysfunction or thrombus. All patients&#xD;
      underwent TTE and TEE examination before and after the thrombolysis sessions. The cross&#xD;
      sectional area and the longest diameter of the thrombus were measured on TEE recordings&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1993</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombolytic success</measure>
    <time_frame>24 hours</time_frame>
    <description>In the absence of fatal or nonfatal major complications;&#xD;
Obstructive thrombus:&#xD;
Doppler documentation of the resolution of increased gradient and decreased valve area.&#xD;
Clinical improvement in symptoms.&#xD;
Reduction by ≥75% in major diameter or area of the thrombus. Complete success was defined when all 3 criteria were met and partial success was defined as less than 3.&#xD;
Nonobstrucive thrombus:&#xD;
Complete success: ≥75% reduction in thrombus area.&#xD;
Partial success: 50%-75% reduction in thrombus area.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-fatal complication rates</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
    <description>Nonfatal major complication: Ischemic stroke, intracranial hemorrhage, embolism (coronary or peripheral), bleeding requiring transfusion.&#xD;
Nonfatal minor complication: Bleeding without need for transfusion, TIA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
    <description>All cause in-hospital mortality.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Prosthetic Valve Thrombosis</condition>
  <arm_group>
    <arm_group_label>rapid streptokinase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose tpa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-hour infusion of 90 mg t-PA(Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>slow streptokinase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>half-dose slow infusion tpa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose slow infusion tpa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6-hour infusion of 25 mg t-PA(Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Streptokinase</intervention_name>
    <description>3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units)</description>
    <arm_group_label>rapid streptokinase</arm_group_label>
    <other_name>Streptase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Streptokinase</intervention_name>
    <description>24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).</description>
    <arm_group_label>slow streptokinase</arm_group_label>
    <other_name>Streptase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue plasminogen activator</intervention_name>
    <description>5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)</description>
    <arm_group_label>high dose tpa</arm_group_label>
    <other_name>ACTILYSE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue Plasminogen Activator</intervention_name>
    <description>6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).</description>
    <arm_group_label>half-dose slow infusion tpa</arm_group_label>
    <other_name>ACTILYSE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue Plasminogen Activator</intervention_name>
    <description>6-hour infusion of 25 mg t-PA (Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).</description>
    <arm_group_label>low dose slow infusion tpa</arm_group_label>
    <other_name>ACTILYSE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with prosthetic valve thrombosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Large left atrial thrombus&#xD;
&#xD;
          -  Recent (&lt;3 weeks) ischemic stroke&#xD;
&#xD;
          -  Hemorrhagic stroke&#xD;
&#xD;
          -  Early (&lt;4 days) postoperative period&#xD;
&#xD;
          -  Traumatic accident &lt;4 weeks&#xD;
&#xD;
          -  Bleeding diathesis †&#xD;
&#xD;
          -  İntracranial mass&#xD;
&#xD;
          -  Active internal bleed&#xD;
&#xD;
          -  Aortic dissection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Ozkan, Assoc.Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kosuyolu Kartal Heart Training and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kosuyolu Kartal Heart Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34844</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Ozkan M, Kaymaz C, Kirma C, Sönmez K, Ozdemir N, Balkanay M, Yakut C, Deligönül U. Intravenous thrombolytic treatment of mechanical prosthetic valve thrombosis: a study using serial transesophageal echocardiography. J Am Coll Cardiol. 2000 Jun;35(7):1881-9.</citation>
    <PMID>10841239</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <last_update_submitted>October 11, 2011</last_update_submitted>
  <last_update_submitted_qc>October 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>MEHMET OZKAN</investigator_full_name>
    <investigator_title>Principal Investigator, MD., FESC., Assoc. Prof,. Head of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Prosthetic valve</keyword>
  <keyword>thrombosis</keyword>
  <keyword>TROIA</keyword>
  <keyword>tPA</keyword>
  <keyword>TEE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Streptokinase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

